Plain-English translation of NCT07694674 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study looks at whether two different types of preventive biologic medications—anti-TNF agents like or , and non-anti-TNF agents like or ustekinumab—work equally well at stopping Crohn's disease from returning after intestinal surgery. Researchers will review medical records and endoscopy results from about 198 patients to see which medication group had better outcomes in preventing recurrence over the first 6 to 12 months after surgery.
After surgery for Crohn's disease, the condition often comes back. Doctors currently use different preventive medications to try to stop this, but it's not clear which type of medication works better, so this study aims to provide real-world evidence to help guide treatment choices.
You likely qualify if…
You likely don't qualify if…
You would not receive any new treatment or make any new visits—this is a retrospective study that reviews your existing medical records. Researchers will gather information about your surgery, which preventive medication you received after surgery, your colonoscopy results or other test results from 6 to 12 months after surgery, and whether your disease came back. The study may also look at imaging scans, blood work, or tissue samples that were already collected as part of your regular care.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
China